Pop­u­la­tion phar­ma­co­ki­net­ics: Drug­mak­ers seek clar­i­ty and ad­di­tions to re­vised FDA guid­ance

About a dozen drug­mak­ers and in­dus­try groups re­cent­ly of­fered their opin­ions on a re­vised FDA draft guid­ance re­lat­ed to pop­u­la­tion phar­ma­co­ki­net­ics (PK) analy­ses sub­mit­ted as part of new drug ap­pli­ca­tions and bi­o­log­ic li­cense ap­pli­ca­tions.

The com­ments large­ly seek spe­cif­ic tweaks to the 23-page re­vised draft, which was re­leased in Ju­ly, al­though some of the com­ments al­so seek fur­ther clar­i­ty and new ad­di­tions to the guid­ance.

In­dus­try group PhRMA, for in­stance, rec­om­mends that the FDA add more spe­cif­ic ex­am­ples or lit­er­a­ture ref­er­ences through­out “to pro­vide de­tail to the high-lev­el rec­om­men­da­tions and to sup­port the tech­ni­cal state­ments.” The FDA al­so should pro­vide spe­cif­ic ex­am­ples of where pop­u­la­tion PK da­ta may al­le­vi­ate the need for a post­mar­ket­ing re­quire­ment or post­mar­ket­ing com­mit­ment, PhRMA says.

Bay­er, mean­while, takes is­sue with the FDA’s in­clu­sion of an ex­ec­u­tive sum­ma­ry in the pop­u­la­tion PK re­port that should fo­cus on the key find­ings af­fect­ing ap­proval or la­bel de­ci­sion or any oth­er rec­om­men­da­tion based on the pop­u­la­tion PK analy­sis.

“Al­though Bay­er agrees that an ex­ec­u­tive sum­ma­ry could be ben­e­fi­cial, the pop­u­la­tion PK re­port is not the cor­rect place. Clin­i­cal in­ter­pre­ta­tion and la­bel de­ci­sion re­quire, in gen­er­al, an as­sess­ment of the all of the da­ta e.g. the re­sult of ex­po­sure re­sponse analy­sis and clin­i­cal safe­ty and ef­fi­ca­cy re­sults of the piv­otal study needs to be avail­able. Very of­ten pop­u­la­tion PK mod­els are de­vel­oped at dif­fer­ent stages of drug de­vel­op­ment and re­port­ed ear­li­er,” Bay­er adds.

The com­pa­ny al­so rais­es the con­cern that the struc­ture of the re­port will not be aligned with the Eu­ro­pean Med­i­cines Agency and Japan’s PM­DA guide­line, as well as the gen­er­al struc­ture of clin­i­cal re­ports.

In ad­di­tion, Astel­las seeks fur­ther specifics from the FDA, not­ing that the draft in­cludes “sub­jec­tive and non-quan­ti­ta­tive terms,” such as “ad­e­quate,” “suf­fi­cient,” “rel­e­vant” and “nar­row.”

“While we ap­pre­ci­ate that the Agency means for the guid­ance to be flex­i­bly in­ter­pret­ed, more quan­ti­ta­tive terms or sug­gest­ed ranges would be ap­pre­ci­at­ed,” Astel­las says.

Pfiz­er pro­pos­es adding a new sec­tion to the draft, ti­tled: “A. Scope of Da­ta for In­clu­sion in Pop­u­la­tion PK Analy­sis” to dis­cuss the use of da­ta from healthy vol­un­teer tri­als “to sup­port the struc­tur­al mod­el and aid com­par­i­son be­tween dif­fer­ent pop­u­la­tions be­fore the cur­rent sec­tion A on study sub­jects and co­vari­ates.”

And Re­gen­eron, among oth­er com­ments, rec­om­mends re­struc­tur­ing the rec­om­men­da­tions for the as­sess­ment of the ef­fects of co­vari­ates “such that all dis­cus­sions are pooled in­to a ded­i­cat­ed sec­tion spe­cif­ic to this top­ic. Such a sec­tion will pro­vide Spon­sors with a clear and con­cise re­source to guide the writ­ing of this com­po­nent of the pop­u­la­tion PK re­port in prepa­ra­tion for ap­ply­ing for mar­ket­ing au­tho­riza­tion.”

Com­ments


RAPS: First pub­lished in Reg­u­la­to­ry Fo­cus™ by the Reg­u­la­to­ry Af­fairs Pro­fes­sion­als So­ci­ety, the largest glob­al or­ga­ni­za­tion of and for those in­volved with the reg­u­la­tion of health­care prod­ucts. Click here for more in­for­ma­tion.

Biogen CEO Michel Vounatsos (via Getty Images)

With ad­u­canum­ab caught on a cliff, Bio­gen’s Michel Vounatsos bets bil­lions on an­oth­er high-risk neu­ro play

With its FDA pitch on the Alzheimer’s drug aducanumab hanging perilously close to disaster, Biogen is rolling the dice on a $3.1 billion deal that brings in commercial rights to one of the other spotlight neuro drugs in late-stage development — after it already failed its first Phase III.

The big biotech has turned to Sage Therapeutics for its latest deal, close to a year after the crushing failure of Sage-217, now dubbed zuranolone, in the MOUNTAIN study.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 94,200+ biopharma pros reading Endpoints daily — and it's free.

Pascal Soriot (AP Images)

UP­DAT­ED: As­traZeneca, Ox­ford on the de­fen­sive as skep­tics dis­miss 70% av­er­age ef­fi­ca­cy for Covid-19 vac­cine

On the third straight Monday that the world wakes up to positive vaccine news, AstraZeneca and Oxford are declaring a new Phase III milestone in the fight against the pandemic. Not everyone is convinced they will play a big part, though.

With an average efficacy of 70%, the headline number struck analysts as less impressive than the 95% and 94.5% protection that Pfizer/BioNTech and Moderna have boasted in the past two weeks, respectively. But the British partners say they have several other bright spots going for their candidate. One of the two dosing regimens tested in Phase III showed a better profile, bringing efficacy up to 90%; the adenovirus vector-based vaccine requires minimal refrigeration, which may mean easier distribution; and AstraZeneca has pledged to sell it at a fraction of the price that the other two vaccine developers are charging.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 94,200+ biopharma pros reading Endpoints daily — and it's free.

John Maraganore, Alnylam CEO (Scott Eisen/Bloomberg via Getty Images)

UP­DAT­ED: Al­ny­lam gets the green light from the FDA for drug #3 — and CEO John Maraganore is ready to roll

Score another early win at the FDA for Alnylam.

The FDA put out word today that the agency has approved its third drug, lumasiran, for primary hyperoxaluria type 1, better known as PH1. The news comes just 4 days after the European Commission took the lead in offering a green light.

An ultra rare genetic condition, Alnylam CEO John Maraganore says there are only some 1,000 to 1,700 patients in the US and Europe at any particular point. The patients, mostly kids, suffer from an overproduction of oxalate in the liver that spurs the development of kidney stones, right through to end stage kidney disease.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 94,200+ biopharma pros reading Endpoints daily — and it's free.

Covid-19 roundup: Eu­rope pur­chas­es 80M dos­es of Mod­er­na's vac­cine; CO­V­AXX se­cures $2.8B in emerg­ing mar­ket pre-or­ders

With the announcement of its vaccine efficacy data last week, Moderna is starting to line up customers for its Covid-19 mRNA jabs.

The Massachusetts-based biotech announced Wednesday it has agreed to sell an initial round of 80 million doses to the European Commission, with the option to double the amount to 160 million. Once the member states rubber stamp the approval, the deal will be finalized.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 94,200+ biopharma pros reading Endpoints daily — and it's free.

The ad­u­canum­ab co­nun­drum: The PhI­II failed a clear reg­u­la­to­ry stan­dard, but no one is cer­tain what that means any­more at the FDA

Eighteen days ago, virtually all of the outside experts on an FDA adcomm got together to mug the agency’s Billy Dunn and the Biogen team when they presented their upbeat assessment on aducanumab. But here we are, more than 2 weeks later, and the ongoing debate over that Alzheimer’s drug’s fate continues unabated.

Instead of simply ruling out any chance of an approval, the logical conclusion based on what we heard during that session, a series of questionable approvals that preceded the controversy over the agency’s recent EUA decisions has come back to haunt the FDA, where the power of precedent is leaving an opening some experts believe can still be exploited by the big biotech.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Leonard Schleifer, Regeneron CEO (Andrew Harnik/AP)

Trail­ing Eli Lil­ly by 12 days, Re­gen­eron gets the FDA OK for their Covid-19 an­ti­body cock­tail

A month and a half after becoming the experimental treatment of choice for a newly diagnosed president, Regeneron’s antibody cocktail has received emergency use authorization from the FDA. It will be used to treat non-hospitalized Covid-19 patients who are at high-risk of progressing.

Although the Rgeneron drug is not the first antibody treatment authorized by the FDA, the news comes as a significant milestone for a company and a treatment scientists have watched closely since the outbreak began.

The flu virus (CDC)

Roche tacks on an­oth­er Xofluza in­di­ca­tion as flu sea­son meets pan­dem­ic

Xofluza was heralded as the first new flu drug in 20 years when it got the FDA OK back in 2018. But even so, Roche saw tough competition from cheaper Tamiflu generics that appeared to be nearly as — if not just as — effective.

Now, the pharma says the drug also can be used to prevent influenza after exposure, snagging a new approval and adding to Xofluza’s appeal as flu season meets the pandemic.

Jason Kelly, Ginkgo Bioworks CEO (Kyle Grillot/Bloomberg via Getty Images)

Af­ter Ko­dak de­ba­cle, US lends $1.1B to a syn­thet­ic bi­ol­o­gy com­pa­ny and their big Covid-19, mR­NA plans

In mid-August, as Kodak’s $765 million government-backed push into drug manufacturing slowly fell apart in national headlines, Ginkgo Bioworks CEO Jason Kelly got a message from his company’s government liaison: HHS wanted to know if they, too, might want a loan.

The government’s decision to lend Kodak three quarters of a billion dollars raised eyebrows because Kodak had never made drugs before. But Ginkgo, while not a manufacturing company, had spent the last decade refining new ways to produce materials inside cells and building automated facilities across Boston.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 94,200+ biopharma pros reading Endpoints daily — and it's free.

FDA hands Liq­uidia and Re­vance a CRL and de­fer­ral, re­spec­tive­ly, as Covid-19 cre­ates in­spec­tion chal­lenge

Two biotechs said they got turned away by the FDA on Wednesday, in part due to pandemic-related travel restrictions.

North Carolina-based Liquidia Technologies was handed a CRL for its lead pulmonary arterial hypertension drug, citing the need for more CMC data and on-site pre-approval inspections, which the FDA hasn’t been able to conduct due to travel restrictions. The agency also deferred its decision on Revance Therapeutics’ BLA for its frown line treatment, because it needs to inspect the company’s northern California manufacturing facility. The action, Revance emphasized, was not a CRL.